Home FDA labels 3d911d81-7305-095c-e054-00144ff8d46c FDA label 3d911d81-7305-095c-e054-00144ff8d46c openFDA label record# This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)
SPL set ID eda86726-cebb-47f5-ac74-73cacdf632a2
SPL ID 3d911d81-7305-095c-e054-00144ff8d46c
Version 2
Effective date 2016-09-28
Source export date 2026-10-12
Source partition 1
Source file https://download.open.fda.gov/drug/label/drug-label-0001-of-0014.json.zip
Source object key raw/openfda/drug-label/2026-10-12/7928c8e8c6256620071a8b7e5b93eb8dfa543649c08d17a01ea02251012ba58c/drug-label-0001-of-0014.json.zip
Source manifest SHA-256 7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
Import run 20261013T011858Z
Imported at 2026-10-13 01:26:11 Harmonized identifier links# Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
Harmonized identifiers page 1 of 1 · 2 matching rows.
Warnings cross-check# openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Warnings sections page 1 of 1 · 1 matching rows.
warnings WARNINGS WARNINGSandPRECAUTIONS), including thyroid nodules (seeWARNINGS andPRECAUTIONS), subacute or chronic lymphocyticthyroiditis (Hashimoto222s thyroiditis), multinodular goiter (seeWARNINGS andPRECAUTIONS) and, as an adjunct to surgery andradioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. page 3 of 12
Adverse reactions cross-check# openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Adverse reactions sections page 1 of 1 · 1 matching rows.
adverse reactions ADVERSE REACTIONS ADVERSE REACTIONSAdverse reactions associated with levothyroxine therapy are primarily those of hyperthyroidism due to therapeutic
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.